Moderna jumps 11% after final results show its COVID-19 vaccine candidate is 94% effective; FDA filing due

This post was originally published on this site

Moderna biotech lab

  • Moderna jumped 11% on Monday as the company prepared to file for US FDA approval of its coronavirus vaccine to be widely distributed.
  • Studies conducted on 196 people show the vaccine shot is more than 94% effective at protecting people from becoming ill with the virus.
  • Visit Business Insider’s homepage for more stories.

Shares in US drugmaker Moderna rose as much as 11% in pre-market trading on Monday after the company prepared to file for US regulatory approval for its COVID-19 vaccine candidate and as final data showed the shot was 94% effective.

More to come.

Bastion Balance Seoul, Korea.